Karyopharm to Participate at Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company specializing in novel cancer therapies, has announced its participation in two upcoming investor conferences in September 2024:
- H.C. Wainwright 26th Annual Global Investment Conference on September 10, featuring a podium presentation at 9:00 a.m. ET
- Baird 2024 Global Healthcare Conference on September 11, with a fireside chat at 10:50 a.m. ET
Live webcasts and slides will be available on the company's website. Karyopharm is known for its oral compound XPOVIO® (selinexor), an XPO1 inhibitor approved in the U.S. for three oncology indications and in other countries as NEXPOVIO®. The company focuses on high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), un'azienda farmaceutica in fase commerciale specializzata in nuove terapie contro il cancro, ha annunciato la sua partecipazione a due conferenze per investitori che si terranno a settembre 2024:
- H.C. Wainwright 26ª Conferenza Globale Annuale sugli Investimenti il 10 settembre, con una presentazione sul podio alle 9:00 ET
- Conferenza Globale sulla Salute Baird 2024 l'11 settembre, con una chiacchierata informale alle 10:50 ET
Le dirette e le diapositive saranno disponibili sul sito web dell'azienda. Karyopharm è conosciuta per il suo composto orale XPOVIO® (selinexor), un inibitore di XPO1 approvato negli Stati Uniti per tre indicazioni oncologiche e in altri paesi come NEXPOVIO®. L'azienda si concentra su tumori ad alto bisogno insoddisfatto, tra cui mieloma multiplo, cancro endometriale, mielofibrosi e DLBCL.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), una compañía farmacéutica en etapa comercial especializada en nuevas terapias contra el cáncer, ha anunciado su participación en dos próximas conferencias para inversionistas en septiembre de 2024:
- H.C. Wainwright 26ª Conferencia Anual Global de Inversiones el 10 de septiembre, con una presentación en el podio a las 9:00 a.m. ET
- Conferencia Global de Salud Baird 2024 el 11 de septiembre, con una charla junto a la chimenea a las 10:50 a.m. ET
Las transmisiones en vivo y las diapositivas estarán disponibles en el sitio web de la compañía. Karyopharm es conocida por su compuesto oral XPOVIO® (selinexor), un inhibidor de XPO1 aprobado en EE. UU. para tres indicaciones oncológicas y en otros países como NEXPOVIO®. La compañía se enfoca en cánceres con alta necesidad no satisfecha, incluyendo mieloma múltiple, cáncer endometrial, mielofibrosis y DLBCL.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI)는 혁신적인 암 치료제를 전문으로 하는 상업 단계의 제약 회사로, 2024년 9월에 열리는 두 개의 투자자 회의에 참여할 것이라고 발표했습니다:
- 9월 10일 H.C. Wainwright 제26회 글로벌 투자 회의, 오전 9시 ET에 발표
- 9월 11일 Baird 2024 글로벌 의료 회의, 오전 10시 50분 ET에 화로 옆 대화
실시간 웹캐스트와 슬라이드는 회사 웹사이트에서 제공될 예정입니다. Karyopharm은 미국에서 세 가지 종양학 적응증에 대해 승인된 XPO1 억제제인 경구 화합물 XPOVIO® (selinexor)로 잘 알려져 있습니다. 이 회사는 다발성 골수종, 자궁내막암, 골수섬유증 및 DLBCL과 같은 충족되지 않은 높은 필요의 암에 중점을 두고 있습니다.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), une entreprise pharmaceutique en phase commerciale spécialisée dans les nouvelles thérapies contre le cancer, a annoncé sa participation à deux conférences pour investisseurs à venir en septembre 2024 :
- 26ème Conférence Annuelle Mondiale d'Investissement H.C. Wainwright le 10 septembre, avec une présentation sur scène à 9h00 ET
- Conférence Mondiale de la Santé Baird 2024 le 11 septembre, avec une discussion informelle à 10h50 ET
Des webcasts en direct et des diapositives seront disponibles sur le site Web de l'entreprise. Karyopharm est connue pour son composé oral XPOVIO® (selinexor), un inhibiteur de XPO1 approuvé aux États-Unis pour trois indications oncologiques et dans d'autres pays sous le nom de NEXPOVIO®. L'entreprise se concentre sur les cancers à besoin non satisfait, y compris le myélome multiple, le cancer de l'endomètre, la myélofibrose et le DLBCL.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), ein pharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf neuartige Krebsbehandlungen spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 angekündigt:
- H.C. Wainwright 26. Jahrestagung zur globalen Investition am 10. September mit einer Podiumspräsentation um 9:00 Uhr ET
- Baird 2024 Globale Gesundheitskonferenz am 11. September mit einem informellen Gespräch um 10:50 Uhr ET
Live-Übertragungen und Folien werden auf der Website des Unternehmens verfügbar sein. Karyopharm ist bekannt für die orale Verbindung XPOVIO® (selinexor), einen XPO1-Inhibitor, der in den USA für drei onkologische Indikationen und in anderen Ländern als NEXPOVIO® zugelassen ist. Das Unternehmen konzentriert sich auf Krebsarten mit einem besonders hohen ungedeckten Bedarf, einschließlich multiplem Myelom, Endometriumkarzinom, Myelofibrose und DLBCL.
- None.
- None.
H.C. Wainwright 26th Annual Global Investment Conference
Format: Podium presentation
Date: Tuesday, September 10, 2024
Time: 9:00 a.m. ET
Baird 2024 Global Healthcare Conference
Format: Fireside chat
Date: Wednesday, September 11, 2024
Time: 10:50 a.m. ET
A live webcast of these events, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay following the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-upcoming-investor-conferences-302235059.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
When is Karyopharm Therapeutics (KPTI) participating in the H.C. Wainwright Global Investment Conference?
What type of presentation will Karyopharm (KPTI) give at the Baird 2024 Global Healthcare Conference?
Where can investors access the webcasts of Karyopharm's (KPTI) conference presentations?
What is Karyopharm Therapeutics' (KPTI) lead compound?
What cancer types does Karyopharm Therapeutics (KPTI) focus on in its pipeline?
